BMS Spends $100m On Orum’s Antibody-Guided Protein Degrader

 
• By Elizabeth Cairns

ORM-6151 combines two hot approaches in cancer R&D, but clinical trials have not yet started.  

Closeup Of Handshake
• Source: Shutterstock

More from Deals

More from Business